+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension



Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension



Pulmonary Circulation 7(4): 803-807



Dasatinib is a small-molecule tyrosine kinase inhibitor used in the treatment of hematological malignancies. Pulmonary arterial hypertension (PAH) is a rare but known complication. The mainstay of treatment is cessation of Dasatinib, and while clinical improvement is rapid, complete hemodynamic resolution of pulmonary hypertension (PH) still remains exceedingly uncommon. We present a case of Dasatinib-induced PAH in a woman with chronic myeloid leukemia, who demonstrated rapid and complete clinical and hemodynamic resolution following treatment with combination pulmonary vasodilator therapy using an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. This case suggests there may be an association between the use of targeted PH medication in combination and the complete resolution of dasatinib-associated PAH, but further investigation is required.

(PDF emailed within 0-6 h: $19.90)

Accession: 059519621

Download citation: RISBibTeXText

PMID: 28644066

DOI: 10.1177/2045893217716659


Related references

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. Case Reports in Cardiology 2018: 3895197, 2018

Comparison of clinical characteristics and survival on patients with idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension during conventional therapy era and targeted therapy era. Zhonghua Xin Xue Guan Bing Za Zhi 42(6): 465-468, 2014

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. American Journal of Cardiology 105(10): 1485-1489, 2010

The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension. Pulmonary Circulation 2(3): 373-378, 2012

Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension. Expert Review of Respiratory Medicine 9(5): 559-569, 2016

Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension. International Heart Journal 56(1): 86-93, 2015

An Analysis of Pulmonary Arterial Hypertension Targeted Medication Before and After Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. Chest Journal 148(4): 1002a-1002b, 2015

Pulmonary hypertension/pulmonary arterial hypertension in congenital heart disease and therapy of pulmonary arterial hypertension in children. Deutsche Medizinische Wochenschrift 139 Suppl 4: S166-S170, 2015

A Step Closer to Mechanism and Additional Targeted Therapies for Pulmonary Arterial Hypertension: Links between Red Blood Cell Lysis and Vascular Dysfunction in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology 59(3): 279-280, 2018

Other causes of pulmonary arterial hypertension: pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, porto-pulmonary hypertension, HIV- associated pulmonary arterial hypertension. Anadolu Kardiyoloji Dergisi 10 Suppl 1: 63-68, 2010

Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. American Heart Journal 162(3): 562-568, 2011

Reverse Right Ventricular Remodeling After Lung Transplantation in Patients With Pulmonary Arterial Hypertension Under Combination Therapy of Targeted Medical Drugs. Circulation Journal 81(3): 383-390, 2017

Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. Chest 150(2): 353-366, 2017

Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia. Japanese Journal of Clinical Hematology 57(8): 999-1003, 2017

Growing number of incident pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Latvia: a shifting epidemiological landscape? Data from a national pulmonary hypertension registry. European Journal of Internal Medicine 2018, 2018